Raphael Jenelten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raphael Jenelten has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Curdin Conrad
Department of Dermatology University Hospital of Lausanne CHUV Lausanne Switzerland
3 shared publications - Jeremy Di Domizio
Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland
3 shared publications - Michel Gilliet
Department of Dermatology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
3 shared publications - Ahmad Yatim
Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland
2 shared publications Ahmad Yatim
Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
1 shared publication- Alessia Baldo
University Hospital of Lausanne 1 Department of Dermatology and Venereology Lausanne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 14 April 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (7)
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protective immunity against SARS-CoV-2 and the association of chilblains with inherited type I interferonopathies, we hypothesized that excessive I-IFN responses to SARS-CoV-2 might underlie the occurrence of chilblains in this context. We identified a transient I-IFN signature in chilblain lesions, accompanied by an acral infiltration of activated plasmacytoid dendritic cells (pDCs). Patients with chilblains were otherwise asymptomatic or had mild disease without seroconversion. Their leukocytes produced abnormally high levels of I-IFN upon TLR7 stimulation with agonists or ssRNA viruses—particularly SARS-CoV-2—but not with DNA agonists of TLR9 or the dsDNA virus HSV-1. Moreover, the patients’ pDCs displayed cell-intrinsic hyperresponsiveness to TLR7 stimulation regardless of TLR7 levels. Inherited TLR7 or I-IFN deficiency confers a predisposition to life-threatening COVID-19. Conversely, our findings suggest that enhanced TLR7 activity in predisposed individuals could confer innate, pDC-mediated, sterilizing immunity to SARS-CoV-2 infection, with I-IFN–driven chilblains as a trade-off.
- 14 April 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (7)
Open AccessEnhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protective immunity against SARS-CoV-2 and the association of chilblains with inherited type I interferonopathies, we hypothesized that excessive I-IFN responses to SARS-CoV-2 might underlie the occurrence of chilblains in this context. We identified a transient I-IFN signature in chilblain lesions, accompanied by an acral infiltration of activated plasmacytoid dendritic cells (pDCs). Patients with chilblains were otherwise asymptomatic or had mild disease without seroconversion. Their leukocytes produced abnormally high levels of I-IFN upon TLR7 stimulation with agonists or ssRNA viruses—particularly SARS-CoV-2—but not with DNA agonists of TLR9 or the dsDNA virus HSV-1. Moreover, the patients’ pDCs displayed cell-intrinsic hyperresponsiveness to TLR7 stimulation regardless of TLR7 levels. Inherited TLR7 or I-IFN deficiency confers a predisposition to life-threatening COVID-19. Conversely, our findings suggest that enhanced TLR7 activity in predisposed individuals could confer innate, pDC-mediated, sterilizing immunity to SARS-CoV-2 infection, with I-IFN–driven chilblains as a trade-off.
- Top Cited PapersOpen Access
- 18 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.
- 18 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Top Cited PapersOpen AccessImmune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.
- Open Access
- 6 March 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (5)
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26
Autoinflammation is a sterile inflammatory process resulting from increased neutrophil infiltration and overexpression of IL-1 cytokines. The factors that trigger these events are, however, poorly understood. By investigating pustular forms of psoriasis, we show that human neutrophils constitutively express IL-26 and abundantly release it from granular stores upon activation. In pustular psoriasis, neutrophil-derived IL-26 drives the pathogenic autoinflammation process by inducing the expression of IL-1 cytokines and chemokines that further recruit neutrophils. This occurs via activation of IL-26R in keratinocytes and via the formation of complexes between IL-26 and microbiota DNA, which trigger TLR9 activation of neutrophils. Thus our findings identify neutrophils as an important source of IL-26 and point to IL-26 as the key link between neutrophils and a self-sustaining autoinflammation loop in pustular psoriasis.
- 6 March 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (5)
Open AccessHuman neutrophils drive skin autoinflammation by releasing interleukin (IL)-26
Autoinflammation is a sterile inflammatory process resulting from increased neutrophil infiltration and overexpression of IL-1 cytokines. The factors that trigger these events are, however, poorly understood. By investigating pustular forms of psoriasis, we show that human neutrophils constitutively express IL-26 and abundantly release it from granular stores upon activation. In pustular psoriasis, neutrophil-derived IL-26 drives the pathogenic autoinflammation process by inducing the expression of IL-1 cytokines and chemokines that further recruit neutrophils. This occurs via activation of IL-26R in keratinocytes and via the formation of complexes between IL-26 and microbiota DNA, which trigger TLR9 activation of neutrophils. Thus our findings identify neutrophils as an important source of IL-26 and point to IL-26 as the key link between neutrophils and a self-sustaining autoinflammation loop in pustular psoriasis.